Aetna modified CPB 1033 covering beremagene geperpavec-svdt (Vyjuvek) for dystrophic epidermolysis bullosa wound treatment, effective January 5, 2026. Here's what billing teams need to do.
Aetna, a CVS Health company, updated its Vyjuvek coverage policy under CPB 1033 Aetna system. This gene therapy product—billed under HCPCS J3401—carries strict prior authorization requirements and a detailed medical necessity checklist. If you bill J3401 for any Aetna commercial member, this update directly affects your approval workflow.
| Field | Detail |
|---|---|
| Payer | Aetna |
| Policy | Beremagene Geperpavec-svdt (Vyjuvek) — CPB 1033 |
| Policy Code | CPB 1033 |
| Change Type | Modified |
| Effective Date | 2026-01-05 |
| Impact Level | High |
| Specialties Affected | Dermatology, Wound Care, Specialty Pharmacy |
| Key Action | Confirm COL7A1 genetic test results and wound eligibility criteria before submitting J3401 claims for any Aetna commercial member |
Aetna Vyjuvek Coverage Criteria and Medical Necessity Requirements 2026
Aetna's Vyjuvek coverage policy sets a high bar. Every single criterion below must be met before Aetna will approve HCPCS J3401 for beremagene geperpavec-svdt. One missing element means a denial.
Confirmed diagnosis with genetic proof. The member must show clinical signs of dystrophic epidermolysis bullosa (DEB)—extensive skin blistering, skin erosions, or scarring. That clinical picture alone isn't enough. The member also needs genetic test results confirming a mutation in the COL7A1 gene. If that lab documentation isn't in the chart, your prior authorization request will fail at the first checkpoint.
Prescriber requirement. This medication must be prescribed by or in active consultation with a dermatologist or wound care specialist. A PCP-only order won't satisfy the criteria. Make sure the prescribing provider's specialty is documented in the precertification submission.
Wound-level eligibility—this is where most denials happen. The member must have one or more open target wounds. Each target wound must meet all three of these conditions simultaneously:
| # | Covered Indication |
|---|---|
| 1 | The wound appears clear—no signs of infection |
| 2 | The wound has adequate granulation tissue and vascularization |
| 3 | The member has no history of squamous cell carcinoma in that specific wound site |
That last point maps directly to ICD-10 Z85.828 (personal history of other malignant neoplasm of skin). If that code is in the member's history and associated with the target wound location, Aetna will not cover Vyjuvek for that wound. Document wound-by-wound—don't treat this as a blanket patient-level exclusion.
Administration setting. Vyjuvek is administered once weekly by a healthcare professional, the member, or a caregiver. The setting can be a clinic or a home setting. Both are acceptable under this coverage policy—but the administration frequency (weekly) and who performs it must be documented.
Healed wounds are excluded. Vyjuvek cannot be administered to wounds that are currently healed. This sounds obvious, but it matters for ongoing authorizations. If a wound closes between authorization approval and the next scheduled treatment, billing J3401 for that wound is not covered.
Precertification contact. Call (866) 752-7021 or fax (888) 267-3277. Statement of Medical Necessity forms are available through Aetna's Specialty Pharmacy Precertification portal. This goes through Aetna's Gene-based, Cellular & Other Innovative Therapies (GCIT) team—a dedicated review unit. Expect a more rigorous review than a standard prior auth.
Aetna Vyjuvek Exclusions and Non-Covered Indications
Aetna's position is direct: all other indications for beremagene geperpavec-svdt beyond DEB wound treatment are considered experimental, investigational, or unproven.
There's no partial coverage gray zone here. If the patient doesn't have confirmed DEB with a COL7A1 mutation, the claim is off the table. If a provider is using Vyjuvek for any other wound etiology or skin condition, don't submit it to Aetna commercial expecting reimbursement—you won't get it.
The wound-level squamous cell carcinoma exclusion also functions as a non-coverage rule. It's not a patient-level disqualifier. A member can have a history of squamous cell carcinoma elsewhere on the body (Z85.828) and still qualify for Vyjuvek—as long as that history doesn't involve the specific wound receiving treatment. Document which wounds are receiving treatment and cross-reference the SCC history by wound location before submitting.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| DEB wound treatment with confirmed COL7A1 mutation, open uninfected wounds with granulation tissue | Covered | J3401, Q81.2, open wound ICD-10 codes | All six criteria must be met; prior auth required through GCIT team |
| DEB wound treatment — wound currently healed at time of administration | Not Covered | J3401 | Vyjuvek cannot be administered to currently healed wounds |
| Target wound with history of squamous cell carcinoma at that site | Not Covered | J3401, Z85.828 | Exclusion is wound-specific, not patient-level |
| Any non-DEB indication for Vyjuvek | Experimental / Not Covered | J3401 | Aetna considers all other uses experimental, investigational, or unproven |
| DEB without COL7A1 genetic confirmation | Not Covered | J3401, Q81.2 | Clinical presentation alone is insufficient — genetic documentation required |
Aetna Vyjuvek Billing Guidelines and Action Items 2026
These steps apply now. The effective date is January 5, 2026—if you're billing J3401 for any Aetna commercial member, your process needs to match this policy today.
| # | Action Item |
|---|---|
| 1 | Audit every active J3401 authorization against the full six-criteria checklist. Don't assume prior approvals issued before January 5, 2026 reflect the updated criteria. Pull the authorization and verify that COL7A1 genetic documentation and wound-level eligibility are on file. If either is missing, get it before the next treatment date. |
| 2 | Build a wound-by-wound documentation standard into your intake process. Each target wound needs its own eligibility notation: wound appearance (clear, no infection), granulation tissue status, and SCC history check for that specific site. A blanket patient-level note won't protect you in a claim review. |
| 3 | Confirm prescriber specialty before submitting precertification. The prescribing provider must be a dermatologist or wound care specialist, or must have a documented consultation with one. Check your EHR's referring/ordering provider field before each prior auth submission. |
| 4 | Flag Z85.828 in your claim scrubber as a wound-level review trigger. When this ICD-10 code appears on a claim with J3401, your billing team should verify that the SCC history is not associated with the target wound site. A claim that auto-routes J3401 with Z85.828 without that check is a denial waiting to happen. |
| 5 | Route all Aetna Vyjuvek authorizations through the GCIT precertification line, not standard prior auth. Call (866) 752-7021 or fax (888) 267-3277. Using the wrong channel delays approval and can create downstream billing problems when the authorization number doesn't match your claim submission. |
| 6 | Document administration frequency and setting in the clinical record. Weekly topical administration by a healthcare professional, the member, or caregiver—in a clinic or home setting—must be supported in the chart. If Aetna audits reimbursement for J3401 claims, that documentation is your first line of defense. |
| 7 | Check wound status before each weekly treatment billing cycle. Vyjuvek cannot be billed for healed wounds. If a wound closes, stop billing J3401 for that wound immediately. Continuing to bill after closure is a compliance exposure, not just a claim denial risk. If you're not sure how this applies to your ongoing authorizations, loop in your compliance officer before the next billing cycle. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Vyjuvek Under CPB 1033
Covered HCPCS Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| J3401 | HCPCS | Beremagene geperpavec-svdt for topical administration, containing nominal 5 x 10^9 pfu/ml vector gen |
Key ICD-10-CM Diagnosis Codes
| Code | Description | Notes |
|---|---|---|
| Q81.2 | Epidermolysis bullosa dystrophica | Primary diagnosis code for DEB — required for coverage |
| Open wound codes (numerous) | Open wounds | Target wound(s) must be documented; specific code depends on wound location and laterality |
| Z85.828 | Personal history of other malignant neoplasm of skin [squamous cell carcinoma] | Disqualifying code at the wound level — triggers wound-by-wound SCC history review |
A note on coding Vyjuvek billing claims: J3401 is the only HCPCS code listed under this policy for beremagene geperpavec-svdt. There are no CPT codes associated with this policy. Aetna does not list a separate administration code in CPB 1033—confirm with your specialty pharmacy and provider billing teams whether an administration charge applies in your setting.
The open wound ICD-10 codes are listed as "numerous options" in the policy. Use the most specific open wound code for each target wound site. Correct laterality and anatomical specificity matter for Aetna commercial claims and will affect how the GCIT team reviews your precertification documentation.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.